Evommune Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire —
PALO ALTO, Calif., Nov. 7, 2025 /PRNewswire/ -- Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the closing of its initial public offering of 10,781,250 shares of...